Gene expression in the developing cerebellum during perinatal hypo- and hyperthyroidism.
The intensity of p75NGFR receptor-like immunoreactivity and the mRNAs encoding p75NGFR, T alpha 1 alpha-tubulin, GAP-43 and the myelin proteins MBP and PLP were measured in the developing cerebellum to study the effects of perinatal thyroid hormone imbalance in rats. Results compared to age-matched controls provide in vivo evidence for differential gene regulation by thyroid hormone in the developing cerebellum. We found that p75NGFR immunoreactivity was strikingly elevated in hypothyroid rats, whereas p75NGFR mRNA content remained only twice as high as that of control levels on postnatal day 15 (P15). When p75NGFR immunoreactivity was still elevated in hypothyroid rats, Purkinje cells exhibited proximal axonal varicosities, axonal twisting and differences in axonal caliber. The mRNAs encoding proteins involved with neurite growth-promoting elements, T alpha 1 alpha-tubulin and GAP-43, were also increased in hypothyroidism, possibly reflecting a neuronal response to a deficiency in, or damage to, cerebellar neurons, or a general delay in their down regulation. Similar increases were not observed for the myelin specific genes. MBP and PLP mRNAs were first detected on P2 of hyperthyroid rats, and they increased with age. Hypo- or hyperthyroidism did not affect the initial onset of MBP and PLP expression, however, hyperthyroidism increased levels of PLP and MBP mRNAs between P2 and P10. By contrast, the most consistent decrease in MBP and PLP mRNAs in rats with thyroid hormone deficiency was observed only on P10. At later times (P15 and P30), the two mRNA levels were similar to controls in all groups. These results are consistent with a role for thyroid hormone in the earlier stages of cerebellar myelination. Hypothryoidism led to specific increases in T alpha 1 alpha-tubulin and GAP-43 mRNAs, and in the immunoreactivity and mRNA levels of p75NGFR receptor--all changes that may play a role in the observed abnormal neuronal outgrowth.
Figueiredo
B C
BC
Department of Pharmacology and Therapeutics, McGill University, Montreal, Que., Canada.
Almazan
G
G
Ma
Y
Y
Tetzlaff
W
W
Miller
F D
FD
Cuello
A C
AC
D000818:Animals; D000831:Animals, Newborn / Q000235:genetics*; D001059:Apoproteins / Q000235:genetics; D002531:Cerebellum / Q000254:growth & development*; D019922:GAP-43 Protein; D015870:Gene Expression; D005815:Genetic Code; D006133:Growth Substances / Q000235:genetics; D006980:Hyperthyroidism / Q000235:genetics*; D007037:Hypothyroidism / Q000235:genetics*; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics; D004676:Myelin Basic Protein / Q000235:genetics; D009185:Myelin Proteins / Q000235:genetics; D018991:Myelin Proteolipid Protein; D009419:Nerve Tissue Proteins / Q000235:genetics; D011689:Purkinje Cells / Q000648:ultrastructure; D012333:RNA, Messenger / Q000235:genetics*; D051381:Rats; D017208:Rats, Wistar; D017475:Receptors, Nerve Growth Factor / Q000032:analysis* / Q000235:genetics; D014404:Tubulin / Q000235:genetics
D001059:Apoproteins; D019922:GAP-43 Protein; D006133:Growth Substances; D008562:Membrane Glycoproteins; D004676:Myelin Basic Protein; D009185:Myelin Proteins; D018991:Myelin Proteolipid Protein; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; D017475:Receptors, Nerve Growth Factor; D014404:Tubulin